Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Stem Cells
HIV Clinical Trial Hailed by California Stem Cell Agency
Posted: July 14, 2013 at 2:59 am
The
California stem cell agency today scored what it called an “important
milestone” with the announcement of the start of a clinical trial
involving a therapy to help protect persons infected with HIV from
the effects of the virus.
California stem cell agency today scored what it called an “important
milestone” with the announcement of the start of a clinical trial
involving a therapy to help protect persons infected with HIV from
the effects of the virus.
The
trial is partially funded from a $20 million award from the stem cell
agency, which is known as CIRM, to researchers
at UCLA and Calimmune, a Tucson, Az.,
company. Calimmune's share of the award was $8.2 million.
trial is partially funded from a $20 million award from the stem cell
agency, which is known as CIRM, to researchers
at UCLA and Calimmune, a Tucson, Az.,
company. Calimmune's share of the award was $8.2 million.
Alan
Trounson, president of the $3 billion state agency, said in a
statement,
Trounson, president of the $3 billion state agency, said in a
statement,
“CIRM
funding of this Phase l/ll trial is an important milestone for us.
One of our goals is to support research that moves the most promising
science out of the lab and into clinical trials in people. To be able
to do that with a disease as devastating as HIV/AIDS highlights the
importance of our funding and the potential impact it could have on
the health of people around the world.”
“The
first patient has begun treatment in a Phase I/II clinical trial
designed to determine whether a pioneering genetic medicine approach
can help to protect individuals infected with HIV from the effects of
the virus. The study, “Safety
Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1
Infection,”
utilizes a gene medicine called Cal-1, developed in the lab of Nobel
Laureate Dr. David
Baltimore and
by Calimmune.”
first patient has begun treatment in a Phase I/II clinical trial
designed to determine whether a pioneering genetic medicine approach
can help to protect individuals infected with HIV from the effects of
the virus. The study, “Safety
Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1
Infection,”
utilizes a gene medicine called Cal-1, developed in the lab of Nobel
Laureate Dr. David
Baltimore and
by Calimmune.”
Baltimore
served on the CIRM board from 2004 until June 6, 2007. He resigned
from the board about
18 months before the application process began for the grant round
that ultimately funded Calimmune, a company he helped to found. He is currently chairman of the Calimmune board.
served on the CIRM board from 2004 until June 6, 2007. He resigned
from the board about
18 months before the application process began for the grant round
that ultimately funded Calimmune, a company he helped to found. He is currently chairman of the Calimmune board.
Asked
for comment, Jeff Sheehy, a member of the CIRM governing
board and communications director for AIDS research at UC San
Francisco, said,
for comment, Jeff Sheehy, a member of the CIRM governing
board and communications director for AIDS research at UC San
Francisco, said,
"This
trial will hopefully offer several important insights into the safety
and feasibility of genetically modifying blood forming stem cells in
an HIV patient as a potential therapy. We are very early in
this research, and with this Phase I trial's goal of establishing
safety and the risks involved, I applaud the courage and altruism
demonstrated by the patients who are willing to participate in this
study."
The Calimmune
press release said
the principal investigators on the clinical trial are Ron
Mitsayasu of
UCLA and Jacob
P. Lalezari of Quest
Clinical Research of
San Francisco. Quest is currently soliciting patients for the
clinical trial as well as UCLA. (Persons interested in participating
in the trial can find email contacts at
this website.
Twelve are needed.)
press release said
the principal investigators on the clinical trial are Ron
Mitsayasu of
UCLA and Jacob
P. Lalezari of Quest
Clinical Research of
San Francisco. Quest is currently soliciting patients for the
clinical trial as well as UCLA. (Persons interested in participating
in the trial can find email contacts at
this website.
Twelve are needed.)
The
principal investigators on the CIRM award are Irvin Chen of
UCLA and Geoff Symonds of Calimmune.
principal investigators on the CIRM award are Irvin Chen of
UCLA and Geoff Symonds of Calimmune.
Here are links to the CIRM press release on the subject and the agency's blog item.
(An earlier version of this story did not include the fact that Calimmune's share of the CIRM award was $8.2 million or the links to the agency press release and blog.)
Posted in Stem Cells, Stem Cell Therapy
Comments Off on HIV Clinical Trial Hailed by California Stem Cell Agency
California Stem Cell Merger: Capricor and Niles Therapeutics
Posted: July 14, 2013 at 2:59 am
Capricor, Inc., a Beverly Hills company
benefiting from $27 million from the California stem cell agency,
this week announced that it is merging with Niles Therapeutic, Inc.,
of San Mateo.
benefiting from $27 million from the California stem cell agency,
this week announced that it is merging with Niles Therapeutic, Inc.,
of San Mateo.
Linda Marban Capricor photo |
The Capricor story and its treatment
for heart disease have been highlighted (see here and here) by the $3
billion state research agency, which is partially funding a clinical
trial for the firm. The firm sprang from work by Eduardo Marban of
Cedars-Sinai in Los Angeles, one of Capricor's founders. He received
$6.9 million for his early and current work. Capricor was awarded
$19.8 million more.
for heart disease have been highlighted (see here and here) by the $3
billion state research agency, which is partially funding a clinical
trial for the firm. The firm sprang from work by Eduardo Marban of
Cedars-Sinai in Los Angeles, one of Capricor's founders. He received
$6.9 million for his early and current work. Capricor was awarded
$19.8 million more.
Capricor, a privately held firm, and
the publicly traded Niles announced on Monday that they were merging.
The new company will be known as Capricor Therapeutics, Inc., and will
be based in San Mateo.
the publicly traded Niles announced on Monday that they were merging.
The new company will be known as Capricor Therapeutics, Inc., and will
be based in San Mateo.
The new firm will be publicly traded
with Capricor CEO Linda Marban as the new CEO.
with Capricor CEO Linda Marban as the new CEO.
The new board of directors will have
two members from Niles and seven from Capricor, including its
executive chairman, Frank Litvack, who was an unsuccessful candidate for chairman of the stem cell agency board in 2011.
two members from Niles and seven from Capricor, including its
executive chairman, Frank Litvack, who was an unsuccessful candidate for chairman of the stem cell agency board in 2011.
The merger press release said that the
new company “should
have better access to capital, more potential for steady pipeline
development and more risk diversification."
new company “should
have better access to capital, more potential for steady pipeline
development and more risk diversification."
On completion of the merger, a joint
press release said,
press release said,
“Nile
will issue to Capricor stockholders shares of Nile common stock such
that Capricor stockholders will own approximately 90% of the combined
company's outstanding shares, and Nile stockholders will own
approximately 10%, calculated in each case on a fully-diluted basis
assuming the issuance of shares underlying options and warrants.
Options of Capricor will be assumed by Nile and become options to
acquire stock of Nile.”
Linda Marban said,
"Capricor's
and Nile's product portfolios complement each other well, as our
therapies will address both the underlying causes and debilitating
effects of heart disease. Capricor's CDCs are allogeneic cardiac
derived stem cells that aim to attenuate and potentially improve
damage to the heart that can result in heart failure, while Nile's
cenderitide is intended to treat patients following hospital
discharge from an acute episode of heart failure."
Niles' stock price stood at $0.04
recently. Its 52 week high was $0.20 and the 52-week low was $0.02.
recently. Its 52 week high was $0.20 and the 52-week low was $0.02.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on California Stem Cell Merger: Capricor and Niles Therapeutics
Eggs and Cash: Stem Cell Agency Considering Easing Restrictions on Stem Cell Lines Derived Using Payments
Posted: July 14, 2013 at 2:59 am
The California stem cell agency is
moving to remove an absolute ban on use of stem cell lines derived
from eggs from women who have been paid to provide them.
moving to remove an absolute ban on use of stem cell lines derived
from eggs from women who have been paid to provide them.
The action comes as state legislation
is headed for Gov. Jerry Brown's desk that would permit payments for
eggs to be used in research that is not funded by the agency. The measure (AB926) would not alter the separate ban on egg payments
involving research funded by the $3 billion stem cell agency.
is headed for Gov. Jerry Brown's desk that would permit payments for
eggs to be used in research that is not funded by the agency. The measure (AB926) would not alter the separate ban on egg payments
involving research funded by the $3 billion stem cell agency.
Under a proposal that will come before the agency's standards group July 24, CIRM's governing board could
approve the use of stem cell lines derived as a result of payment to
women. Board action would be based on whether stem cell lines would
“advance CIRM's mission” and would follow a staff evaluation
involving scientific and ethical issues.
approve the use of stem cell lines derived as a result of payment to
women. Board action would be based on whether stem cell lines would
“advance CIRM's mission” and would follow a staff evaluation
involving scientific and ethical issues.
Over recent years, stem cell
researchers around the country have reported that they are not able
to obtain sufficient eggs without payment. And earlier this year,
paid egg providers were used in research in Oregon that cloned human stem cells, a feat that researchers have struggled with for years.
researchers around the country have reported that they are not able
to obtain sufficient eggs without payment. And earlier this year,
paid egg providers were used in research in Oregon that cloned human stem cells, a feat that researchers have struggled with for years.
A CIRM staff report said that the
Oregon research has “generated scientific interest among CIRM
grantees and the desire to utilize derived SCNT lines. CIRM’s
current policy prohibits the use of the (Oregon) SCNT lines because
oocyte donors were financially compensated. CIRM requests the Medical
and Ethical Standards Working Group (SWG) revaluate this prohibition
with regard to CIRM grantees ability to utilize the resulting lines
in light of recent scientific and policy developments.”
Oregon research has “generated scientific interest among CIRM
grantees and the desire to utilize derived SCNT lines. CIRM’s
current policy prohibits the use of the (Oregon) SCNT lines because
oocyte donors were financially compensated. CIRM requests the Medical
and Ethical Standards Working Group (SWG) revaluate this prohibition
with regard to CIRM grantees ability to utilize the resulting lines
in light of recent scientific and policy developments.”
Last month, the California Stem Cell
Report queried the agency concerning earlier, sketchy information onthe CIRM blog about a possible change in its compensation rules. We
asked whether the agency was considering “sidestepping” the ban
on compensation. Kevin McCormack, a CIRM spokesman, said, “No, not
at all.” He said it would be premature to elaborate until a firm
proposal was ready.
Report queried the agency concerning earlier, sketchy information onthe CIRM blog about a possible change in its compensation rules. We
asked whether the agency was considering “sidestepping” the ban
on compensation. Kevin McCormack, a CIRM spokesman, said, “No, not
at all.” He said it would be premature to elaborate until a firm
proposal was ready.
The staff proposal to be considered on
July 24 said,
July 24 said,
“Proposition 71’s 'prohibition on
compensation' compels the ICOC(the agency's governing board) to adopt
standards 'prohibiting compensation to research donors.' This
requirement has been consistently interpreted to prohibit the use of
CIRM funds to financially compensate oocyte (or other cell or tissue)
donors. In 2006, this interpretation was extended to exclude from
use, in CIRM-funded research, any stem cell line where research
donors were financially compensated, even if the derivation was done
without the use of CIRM funds. Proposition 71, however, does not
compel the ICOC (the agency's governing board) to prohibit the use of
stem cell lines where financial compensation is provided to the
oocyte donors, provided that CIRM funds are not used to compensate
the donors or derive the lines.”
The July 24 meeting will be held in San
Francisco. No remote teleconference locations have been announced. If approved, the changes would likely be considered July 25 by the full agency board.
Francisco. No remote teleconference locations have been announced. If approved, the changes would likely be considered July 25 by the full agency board.
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/BF3kpSRnKXQ/eggs-and-cash-stem-cell-agency.html
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Eggs and Cash: Stem Cell Agency Considering Easing Restrictions on Stem Cell Lines Derived Using Payments
California Legislation Removing Ban on Payments for Eggs for Research Heads to Governor
Posted: July 14, 2013 at 2:59 am
Legislation to allow women in
California to be paid for their eggs for scientific research is on
its way to Gov. Jerry Brown following final legislative approval last
week.
California to be paid for their eggs for scientific research is on
its way to Gov. Jerry Brown following final legislative approval last
week.
Sponsors of the bill, a national
fertility industry organization, expect the governor later this month
to sign the measure, which would go into effect next year.
fertility industry organization, expect the governor later this month
to sign the measure, which would go into effect next year.
The measure, AB 926 by Assemblywoman
Susan Bonilla, D-Concord, would repeal a ban on payments to women who
provide eggs for scientific research. However, the measure would not
affect the ban on payments to egg providers in research funded by the
$3 billion California stem cell agency. That ban is covered by a
separate legal provision. Stem cell researchers around the country have complained that they they cannot get eggs without payment.
Susan Bonilla, D-Concord, would repeal a ban on payments to women who
provide eggs for scientific research. However, the measure would not
affect the ban on payments to egg providers in research funded by the
$3 billion California stem cell agency. That ban is covered by a
separate legal provision. Stem cell researchers around the country have complained that they they cannot get eggs without payment.
Women in California can be paid for
providing eggs for reproductive purposes. According to a legislative analysis, payments can run as high as $50,000 for women with special
characteristics but average around $9,000 for each session, which can
generate more than one egg.
providing eggs for reproductive purposes. According to a legislative analysis, payments can run as high as $50,000 for women with special
characteristics but average around $9,000 for each session, which can
generate more than one egg.
The sponsor of the legislation is the
American Society for Reproductive Medicine of Alabama, whose members
represent a wide swath of the $5 billion-a-year fertility business.
The measure would open new business avenues for the industry.
American Society for Reproductive Medicine of Alabama, whose members
represent a wide swath of the $5 billion-a-year fertility business.
The measure would open new business avenues for the industry.
Bonilla argues that the measure allows women to be treated on the same footing as men who provide sperm for
research and would encourage more research into reproductive health issues.
research and would encourage more research into reproductive health issues.
Opponents argue that the safety of the
egg production procedures has not been well-established including
their long-term impact. They also argue that allowing payment would
lead to exploitation of poor and minority women.
egg production procedures has not been well-established including
their long-term impact. They also argue that allowing payment would
lead to exploitation of poor and minority women.
The bill received its final
legislative approval on July 1 when the Senate passed it on a 24-9
vote.
legislative approval on July 1 when the Senate passed it on a 24-9
vote.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on California Legislation Removing Ban on Payments for Eggs for Research Heads to Governor
Unique route to stem cells: Designer proteins developed to deliver stem cells
Posted: July 13, 2013 at 12:44 am
Javascript is currently disabled in your web browser. For full site functionality, it is necessary to enable Javascript. In order to enable it, please see these instructions. 15 hours ago The schematic diagram of designer proteins and their binding sites at the Oct4 distal enhancer.
(Phys.org) Researchers have developed a new method to produce stem cells using designed proteins. The new system is more precise and more natural than current techniques and the team believe it could be a more efficient and safer route to producing stem cells.
Stem cells have the potential to be used to replace dying or damaged cells with healthy cells. This repair could have wide-ranging uses in medicine such as organ replacement, bone replacement and treatment of neurodegenerative diseases. This study brings closer to realising the full potential of stem cell technology.
"We have gone down a completely different road to standard practices to produce stem cells from adult cells," says Dr Pentao Liu, senior author from the Wellcome Trust Sanger Institute. "Current techniques to reprogramme cells are inefficient and it's imperative to find other ways to create stem cells."
"We hope that our novel approach to reprogramming cells into stem cells will become a new and safer alternative to current practices."
The team looked at proteins called transcription factors, which regulate the activity of all human genes. Each transcription factor acts to modify the activity of several or many genes.
A key set of these transcription factors are able to convert or reprogramme adult cells into induced pluripotent stem cells or iPS cells. However, these factors also act on many genes other than those involved in reprogramming.
The team developed artificial designer transcription factors to target those key reprogramming genes more accurately, minimizing activity on other genes.
"This is a promising and exciting development in our attempt to produce iPS cells that lend themselves in practical applications," says Dr Xuefei Gao, first author from the Wellcome Trust Sanger Institute. "We have shown that targeting gene-control regions, called enhancers, in this structured way is a very effective in controlling a gene and reprogramming cells to become iPS cells."
In conventional methods, the transcription factors used to programme cells take part in complicated ways - and target many different parts of the genome - as they are used to reprogramme the cells to become stems cells. As a result, the throughput of successfully reprogrammed cells can be low and the additional number of steps can have associated risks, such as affecting genes that can influence tumour development.
Originally posted here:
Unique route to stem cells: Designer proteins developed to deliver stem cells
Posted in Stem Cells
Comments Off on Unique route to stem cells: Designer proteins developed to deliver stem cells
Global Stem Cells Market – Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 – 2018
Posted: July 13, 2013 at 12:44 am
Albany, New York (PRWEB) July 12, 2013
According to a new market report published by Transparency Market Research "Stem Cells Market (Adult, Human Embryonic , Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell Production, Cell Acquisition, Expansion, Sub-Culture)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the market for stem cells was valued at USD 26.23 billion in 2011 and is expected to reach an estimated value of USD 119.51 billion in 2018, growing at a CAGR of 24.2% from 2012 to 2018.
Related Report : Coronary Stents Market http://www.transparencymarketresearch.com/coronary-stents-market.html
Stem cells are undifferentiated cells which are capable of differentiating into any type of cell that make-up the human body and thus, are capable of producing non-regenerative cells such as neural and myocardial cells. This report estimates the market for global stem cells in terms of revenue (USD billion) for the period 2012 2018, keeping 2011 as the base year.
The global stem cells market is mainly segmented into four major sub-types namely market by products, market by technology, market by applications and market by geography. The market by products is segmented into three sub-types, namely adult stem cells, human embryonic stem cells and other type of stem cells. Adult stem cells are further segmented into hematopoietic stem cells, mesenchymal stem cells, neuronal stem cells, dental stem cells and umbilical cord stem cells.
Browse Bolg : Medical Devices Market Research Reports http://medical-devices-market-reports.blogspot.com/
The other types of stem cells include induced pluripotent stem cells, natural rosette cells and very small embryonic like stem cells. The global stem cells market by technology is segmented into four sub-types, namely cell acquisition, cell production, cryopreservation and expansion and sub-culture. Cell acquisition is further segmented into three sub-types, namely bone marrow harvest, apheresis and umbilical cord blood. Cell production is further segmented into therapeutic cloning, in vitro fertilization, isolation and cell culture.
Browse the full report with TOC at http://www.transparencymarketresearch.com/stem-cells-market.html.
The global stem cells market by application is segmented into regenerative medicines and drug discovery and development. Regenerative medicines are further segmented into ten sub-types, namely neurological disorders, orthopedics, cancer, hematological disorders, cardiovascular diseases, injuries, diabetes, liver disorders, incontinence and other disorders like Crohns disease, infertility, immunodeficiency disorders and organ transplants. The global stem cells market is also segmented on the basis of geography into North America, Europe, Asia and rest of the world (RoW) regions and the market in terms of USD billion is provided in this report. The report highlights the market shares of key players in 2011.
The company profiles for some of the key players, namely Advanced Cell Technology Inc., STEMCELL Technologies Inc., Cellular Engineering Technologies Inc., BioTime Inc., Aastrom Biosciences Inc. and California Stem Cell Inc. in terms of company overview, financial overview, business strategies, recent developments and product portfolio is also covered.
See the original post here:
Global Stem Cells Market - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
Posted in Stem Cells
Comments Off on Global Stem Cells Market – Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 – 2018
Sanger maps unique route to stem cells
Posted: July 13, 2013 at 12:44 am
Cambridge researchers have developed a new method to produce stem cells using designed proteins.
Stem cells have the potential to be used to replace dying or damaged cells with healthy cells. This repair could have wide-ranging uses in medicine such as organ replacement, bone replacement and treatment of neurodegenerative diseases. This study brings closer to realising the full potential of stem cell technology.
We have gone down a completely different road to standard practices to produce stem cells from adult cells, says Dr Pentao Liu, senior author from the Wellcome Trust Sanger Institute.
Current techniques to reprogramme cells are inefficient and its imperative to find other ways to create stem cells. We hope that our novel approach to reprogramming cells into stem cells will become a new and safer alternative to current practices.
The team looked at proteins called transcription factors, which regulate the activity of all human genes. Each transcription factor acts to modify the activity of several or many genes.
A key set of these transcription factors are able to convert or reprogramme adult cells into induced pluripotent stem cells or iPS cells. However, these factors also act on many genes other than those involved in reprogramming.
The team developed artificial designer transcription factors to target those key reprogramming genes more accurately, minimising activity on other genes.
"This is a promising and exciting development in our attempt to produce iPS cells that lend themselves in practical applications, says Dr Xuefei Gao, first author from the Wellcome Trust Sanger Institute. We have shown that targeting gene-control regions, called enhancers, in this structured way is a very effective in controlling a gene and reprogramming cells to become iPS cells.
In conventional methods, the transcription factors used to programme cells take part in complicated ways and target many different parts of the genome as they are used to reprogramme the cells to become stems cells. As a result, the throughput of successfully reprogrammed cells can be low and the additional number of steps can have associated risks, such as affecting genes that can influence tumour development.
The designer transcription factors are extremely accurate. Because this method targets key genes directly and avoids additional genetic detours, it reduces the potential risks linked with standard practices.
Follow this link:
Sanger maps unique route to stem cells
Posted in Stem Cells
Comments Off on Sanger maps unique route to stem cells
Researchers Create Inner Ear Using Stem Cells
Posted: July 13, 2013 at 12:44 am
Featured Article Main Category: Ear, Nose and Throat Also Included In: Stem Cell Research Article Date: 12 Jul 2013 - 2:00 PDT
Current ratings for: Researchers Create Inner Ear Using Stem Cells
5 (1 votes)
Scientists have developed a way of using stem cells to create key structures of the inner ear in mice, publishing their findings in the journal Nature.
The Indiana University researchers found that by using a 3D cell-culture method, they were able to persuade stem cells to develop into inner ear sensory epithelium, which detects head movement, gravity and sound. The epithelium contains hair cells, supporting cells and neurons.
A 3D cell-culture method can more closely copy natural tissues and organs than cells grown two-dimensionally. In 3D cell culture, cells can attach to each other and form natural cell-to-cell attachments.
Karl R. Koeheler, one of the researchers in the study, explains:
"The three-dimensional culture allows the cells to self-organize into complex tissues using mechanical cues that are found during embryonic development."
"We were surprised to see that once stem cells are guided to become inner ear precursors and placed in 3D culture, these cells behave as if they knew not only how to become different cell types in the inner ear, but also how to self-organize into a pattern remarkably similar to the native inner ear."
He adds that their initial goal was to make inner ear precursors, cells from which other cells are formed, in the 3D culture method - but when they did testing, thousands of hair cells were found in the culture dish.
See the original post:
Researchers Create Inner Ear Using Stem Cells
Posted in Stem Cells
Comments Off on Researchers Create Inner Ear Using Stem Cells
Injecting iron supplement lets Stanford scientists track transplanted stem cells
Posted: July 13, 2013 at 12:44 am
Public release date: 12-Jul-2013 [ | E-mail | Share ]
Contact: Bruce Goldman 650-725-2106 Stanford University Medical Center
STANFORD, Calif. A new, noninvasive technique for tracking stem cells after transplantation developed by a cross-disciplinary team of radiologists, chemists, statisticians and materials scientists at the Stanford University School of Medicine could help surgeons determine whether a procedure to repair injured or worn-out knees is successful.
The technique, described in a study to be published online July 12 in Radiology, relies on an imaging agent already approved by the U.S. Food and Drug Administration for an entirely different purpose: anemia treatment. Although this study used rodents, the approach is likely to be adapted for use in humans this fall as part of a clinical trial in which mesenchymal stem cells will be delivered to the site of patients' knee injuries. Mesenchymal stem cells are capable of differentiating into bone and cartilage, as well as muscle, fat and tendon, but not into the other cell types that populate the body.
Every year, arthritis accounts for 44 million outpatient visits and 700,000 knee-replacement procedures. But the early repair of cartilage defects in young patients may prevent further deterioration of the joint and the need for knee replacement later in life, said the study's senior author, Heike Daldrup-Link, MD, PhD, an associate professor of radiology and clinician who splits her time between research and treating pediatric patients.
Mesenchymal stem cells have been used with some success in cartilage-repair procedures. "These cells can be easily derived from bone marrow of patients who are going to undergo the knee-repair procedure," said Daldrup-Link, a member of the Molecular Imaging Program at Stanford. "And they can differentiate into the real-life tissues that compose our joints. But here, too, things can go wrong. The newly transferred cells might fail to engraft, or die. They might migrate away. They could develop into tissues other than cartilage, most commonly fibrous scar tissue."
Relatively few transplanted cells go the distance. The ability to monitor the cells' engraftment after they are deposited at a patient's knee-injury site is therefore essential. With the new technique, magnetic resonance imaging can visualize stem cells for several weeks after they have been implanted, giving orthopaedic surgeons a better sense of whether the transplantation was successful.
Until now, the only ways of labeling mesenchymal stem cells so that they could be noninvasively imaged have required their manipulation in the laboratory. Upon extraction, the delicate cells have to be given to lab personnel, incubated with contrast agents, spun in a centrifuge and washed and returned to the surgeons, who then transplant the cells into a patient.
The new technique involves labeling the cells before extraction, while they reside in the donor's bone marrow. For the study, lead authors Aman Khurana, MD, a postdoctoral scholar, and Fanny Chapelin, a research associate, injected ferumoxytol, an FDA-licensed anemia treatment composed of iron-oxide nanoparticles, into rats prior to extracting bone marrow from them. Then, after enriching the mixture for mesenchymal stem cells, the investigators injected it into the sites of knee injuries in recipient rats. They followed the implanted cells' progress for up to four weeks, comparing the results with those obtained both from cells labeled in laboratory dishes and from unlabeled cells.
Daldrup-Link and others previously have used ferumoxytol for stem-cell labeling in a dish. However, mesenchymal stem cells in a laboratory dish take up very little of this substance. Interestingly, the researchers showed in a series of experiments that, ensconced in donor rats' bone marrow, the same cells are avid ferumoxytol absorbers. Even several weeks after transplantation into the recipient rats' knees, the mesenchymal stem cells retain enough iron to provide a strong MRI signal.
Original post:
Injecting iron supplement lets Stanford scientists track transplanted stem cells
Posted in Stem Cells
Comments Off on Injecting iron supplement lets Stanford scientists track transplanted stem cells
Shestack Resignation Letter: Heartfelt and Eloquent
Posted: July 12, 2013 at 3:59 pm
Jon Shestack(l) with J.T. Thomas, chairman of CIRM, at a 2012 board meeting California Stem Cell Report photo |
Patient advocate Jon Shestack , who
resigned this week as a director of the
California stem cell agency, was on board on Day One in December 2004
when the agency's work began with no offices, no desks, no chairs, no phones and
no ability to even write checks.
resigned this week as a director of the
California stem cell agency, was on board on Day One in December 2004
when the agency's work began with no offices, no desks, no chairs, no phones and
no ability to even write checks.
Shestack's appointment came as a result
of his work in the autism community. He and his wife, Portia Iversen,
founded Cure Autism Now in 1995. A Hollywood film producer, Shestack
rattled cages at CIRM from time to time during his eight years of
service. And earlier this week, he wrote a heartfelt, eloquent
resignation letter, which he provided to the California Stem Cell
Report. The full text can be found below. Here are some excerpts.
of his work in the autism community. He and his wife, Portia Iversen,
founded Cure Autism Now in 1995. A Hollywood film producer, Shestack
rattled cages at CIRM from time to time during his eight years of
service. And earlier this week, he wrote a heartfelt, eloquent
resignation letter, which he provided to the California Stem Cell
Report. The full text can be found below. Here are some excerpts.
“Over eight years there were moments
that were inspiring, some were contentious, and there was a bruising
number of meetings but through it all, the board was involved,
passionate and, will forever be for me, the gold standard when it
comes to integrity.
“The same goes double for the staff –
truly the most excellent, devoted, committed group of people I
have ever had the pleasure of working with.”
“When I started at CIRM, my sweet son
with autism was 12. Now he is 21. Over eight years our family has
learned more about how many are the challenges that await him and how
few the opportunities he has to look forward to. We have seen his
world get smaller and smaller. While my son is special to me. He is
not unique. There are thousands and thousands affected by mental
illness who need a better life.
“Sometimes feel that I have failed
these people, in particular those affected by autism or cerebral
palsy. Though CIRM ran first-rate workshops on these disorders, we
did not do all we could to follow up, put out disease-specific RFAs
and get in proposals that addressed the workshop recommendations. I
wish I had been more persuasive."
“In the movies, the third act is
where the hero takes stock of all the previous wins and losses, all
the hardships and lessons learned, and she puts all that knowledge
together in new, and surprising ways until victory is within reach!
As CIRM enters its third act, I hope it will do the same. I hope it
will challenge itself, always put the urgency of the mission
ahead of everything else and be willing to question the policies that
have been so successful in the past, and consider that new ones may
be needed for the future.
“And this is the future as I see it
for CIRM. We will have faith, but we will continue to earn our
miracles We will use our hearts and our minds to rip those miracles
out of the dreamy future and make them real today. We will seek out
the best scientists and encourage them to use all their wisdom, art
and discernment to bring us cures. And when we have done that, we
will do it again the next day. We will be optimistic, but not
satisfied. We will question authority, despise complacency and above
all love those among us in need of healing--this is the obligation
without end, whose reward is also without end.”
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Shestack Resignation Letter: Heartfelt and Eloquent